Akoya Biosciences (AKYA) said in a Wednesday filing that it received an unsolicited acquisition proposal from an undisclosed third party, which offered $1.40 in cash for each Akoya common share.
The company said its board is reviewing the proposal and has determined that it could lead to a superior proposal as defined under its merger deal with Quanterix (QTRX). Akoya said that there is no guarantee that it would constitute a superior proposal following the review.
Quanterix and Akoya Biosciences announced their updated merger agreement in April, under which Quanterix will issue about 7.76 million shares and pay $20 million in cash to Akoya shareholders.
Akoya said its board continues to recommend the merger deal with Quanterix to its shareholders.
Shares of Akoya Biosciences were up over 25% in recent Wednesday trading.
Price: 1.33, Change: +0.27, Percent Change: +25.38
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。